Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
aTyr Pharma, Inc. (ATYR)
Company Research
Source: GlobeNewswire
SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. (NASDAQ: ATYR) concerning alleged fiduciary breaches tied to disclosures around the Phase 3 EFZO-FIT clinical trial. The relevant class action covers November 7, 2024 through September 12, 2025. What Should Shareholders Do?If you are a current aTyr shareholder and have continuously held your shares before November 7, 2024 and continue to hold your shares, you may have standing to pursue derivative claims on behalf of the Company. For more information please visit our website at: https://www.johnsonfistel.com/investigations/atyr-pharma-inc/ Background of the Investigation According to the allegations, aTyr and certain executives allegedly made false and/or misleading statements concerning: • The design and expectations of the Phase 3 EFZO-FIT trial; • The likelihood that EFZO-FIT would meet its primary steroid-tapering endpoint; • Repres
Show less
Read more
Impact Snapshot
Event Time:
ATYR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATYR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATYR alerts
High impacting aTyr Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATYR
News
- ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud LawsuitPR Newswire
- Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class Action – Contact The Gross Law Firm to Learn MoreGlobeNewswire
- FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr PharmaBusiness Wire
- ATYR DEADLINE ALERT: Hagens Berman Alerts aTyr Pharma (ATYR) Investors of Today’s Lead Plaintiff Deadline in Securities Class ActionGlobeNewswire
- DEADLINE ALERT for MRX, ATYR, and WPP: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersGlobeNewswire
ATYR
Earnings
- 11/6/25 - Miss
ATYR
Sec Filings
- 12/5/25 - Form 8-K
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- ATYR's page on the SEC website